Products › Ipamorelin
Growth Hormone Axis

Ipamorelin

A pentapeptide growth hormone secretagogue studied in preclinical research for its selective ghrelin receptor agonism and minimal effect on cortisol or prolactin.

CAS Number
170851-70-4
Sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular Formula
C38H49N9O5
Molecular Weight
711.9 g/mol
Purity
≥99% (HPLC)
Form
Lyophilized powder
Vial Content
10mg/10mg per vial (CJC-1295/Ipamorelin Blend)
Documentation
COA & HPLC Analysis
See our quality assurance & testing process ›

Overview

Ipamorelin is a synthetic pentapeptide belonging to the growth hormone releasing peptide (GHRP) class, developed as a selective ghrelin receptor agonist. It was first characterized in the 1990s as a research tool for studying growth hormone secretagogue pharmacology with a cleaner selectivity profile than earlier GHRPs. Peptide Factory supplies Ipamorelin as a lyophilized powder for laboratory research.

Research Background

Ipamorelin’s pentapeptide structure incorporates non-standard amino acids (Aib, D-2-Nal, D-Phe) that confer both metabolic stability and receptor selectivity. Receptor-binding and functional studies have characterized it as a potent, selective agonist at the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by endogenous ghrelin.

Studied Applications

Preclinical research on Ipamorelin has examined:

  • Selective GH secretagogue research — in vitro receptor-binding assays and in vivo rodent models have compared Ipamorelin’s GHS-R1a selectivity against other secretagogues, with published data indicating limited cross-reactivity with ACTH/cortisol pathways.
  • Combination research with GHRH analogs — studies pairing Ipamorelin with GHRH-class peptides (e.g., CJC-1295 no DAC) have investigated synergistic GH pulse amplitude in animal models.
  • Gastrointestinal motility research — as a ghrelin receptor agonist, Ipamorelin has also been studied in gut motility and gastric emptying models given ghrelin’s established role in these processes.

These are laboratory and preclinical findings; Ipamorelin is not approved for human administration and no dosing guidance is provided.

Storage & Handling

Store lyophilized Ipamorelin at -20°C, protected from light and moisture. See our storage and handling guidance for reconstitution protocols.

References

  • Raun, K. et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur. J. Endocrinol. research literature.
  • Gobburu, J. V. et al. Pharmacokinetic/pharmacodynamic modeling of Ipamorelin in animal models.
  • Sinha, D. K. et al. GH secretagogue receptor selectivity research review.

For Research Use Only — Not for Human Consumption.

Frequently Asked

What makes Ipamorelin distinct from other growth hormone secretagogues?
Research literature describes Ipamorelin as a highly selective ghrelin receptor (GHS-R1a) agonist, with studies reporting minimal off-target effects on cortisol, aldosterone, and prolactin secretion compared to earlier-generation secretagogues like GHRP-6.
Is Ipamorelin a growth hormone itself?
No. Ipamorelin is a growth hormone secretagogue — it is studied for its ability to stimulate endogenous GH release via the ghrelin receptor, rather than supplying exogenous growth hormone.

Related Products

For Research Use Only — Not for Human Consumption